These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29574085)

  • 1. Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol: A valuable tool for evaluating progressive supranuclear palsy.
    Weng R; Wei X; Yu B; Zhu S; Yang X; Xie F; Zhang M; Jiang Y; Feng ZP; Sun HS; Xia Y; Jin K; Chan P; Wang Q; Gao X
    Parkinsonism Relat Disord; 2018 Jul; 52():37-42. PubMed ID: 29574085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study.
    Wang R; Chen Z; Fu Y; Wei X; Liao J; Liu X; He B; Xu Y; Zou J; Yang X; Weng R; Tan S; McElroy C; Jin K; Wang Q
    Front Aging Neurosci; 2017; 9():26. PubMed ID: 28223934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration.
    Santos-Santos MA; Mandelli ML; Binney RJ; Ogar J; Wilson SM; Henry ML; Hubbard HI; Meese M; Attygalle S; Rosenberg L; Pakvasa M; Trojanowski JQ; Grinberg LT; Rosen H; Boxer AL; Miller BL; Seeley WW; Gorno-Tempini ML
    JAMA Neurol; 2016 Jun; 73(6):733-42. PubMed ID: 27111692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of Magnetic Resonance Parkinsonism Index in differentiating progressive supranuclear palsy from Parkinson's disease and controls in Indian patients.
    Sankhla CS; Patil KB; Sawant N; Gupta S
    Neurol India; 2016; 64(2):239-45. PubMed ID: 26954800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of serum cystatin C: A valuable tool for evaluating dyskinesia in Parkinson's disease.
    Dong X; Zheng D; Nao J
    Neurosci Lett; 2019 Jul; 705():172-176. PubMed ID: 31054924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Non-Motor Symptom Profile of Progressive Supranuclear Palsy.
    Chaithra SP; Prasad S; Holla VV; Stezin A; Kamble N; Yadav R; Pal PK
    J Mov Disord; 2020 May; 13(2):118-126. PubMed ID: 32241079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
    Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
    Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy.
    Abate F; Russo M; Ricciardi C; Tepedino MF; Romano M; Erro R; Pellecchia MT; Amboni M; Barone P; Picillo M
    Parkinsonism Relat Disord; 2023 Apr; 109():105345. PubMed ID: 36868037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study.
    Quattrone A; Morelli M; Quattrone A; Vescio B; Nigro S; Arabia G; Nisticò R; Novellino F; Salsone M; Arcuri P; Luca A; Mazzuca A; Alessio C; Rocca F; Caracciolo M
    Parkinsonism Relat Disord; 2020 Mar; 72():1-6. PubMed ID: 32036297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of decline in progressive supranuclear palsy.
    Litvan I; Kong M
    Mov Disord; 2014 Apr; 29(4):463-8. PubMed ID: 24615741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding fatigue in progressive supranuclear palsy.
    Ahn JH; Song J; Lee DY; Youn J; Cho JW
    Sci Rep; 2021 Aug; 11(1):16926. PubMed ID: 34413435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism.
    Mostile G; Nicoletti A; Cicero CE; Cavallaro T; Bruno E; Dibilio V; Luca A; Sciacca G; Raciti L; Contrafatto D; Chiaramonte I; Zappia M
    Neurol Sci; 2016 Apr; 37(4):591-5. PubMed ID: 26820655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain in progressive supranuclear palsy.
    Donker Kaat L; Meeter LH; Chiu WZ; Melhem S; Boon AJW; Blennow K; Zetterberg H; van Swieten JC
    Parkinsonism Relat Disord; 2018 Nov; 56():98-101. PubMed ID: 29937097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
    Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
    Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.
    Tsai RM; Lobach I; Bang J; Whitwell JL; Senjem ML; Jack CR; Rosen H; Miller B; Boxer AL;
    Parkinsonism Relat Disord; 2016 Jul; 28():29-35. PubMed ID: 27132501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.
    Bang J; Lobach IV; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Gold M; Morimoto BH; Boxer AL;
    Parkinsonism Relat Disord; 2016 Jul; 28():41-48. PubMed ID: 27172829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
    Hewer S; Varley S; Boxer AL; Paul E; Williams DR;
    Mov Disord; 2016 Oct; 31(10):1574-1577. PubMed ID: 27324431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential significance of hepcidin evaluation in progressive supranuclear palsy.
    Alster P; Otto-Ślusarczyk D; Wiercińska-Drapało A; Struga M; Madetko-Alster N
    Brain Behav; 2024 Jun; 14(6):e3552. PubMed ID: 38953731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.